Teva CEO on Drug Pricing, Generics, Supply Shortages

The transcript discusses Teva's impressive share performance and future strategies, focusing on maintaining momentum through its innovative portfolio and pipeline. It addresses challenges in the generics market due to price deflation and highlights the importance of global scale and a deep pipeline. The discussion also covers Adderall supply issues, potential over-prescription, and the role of government quotas. Teva's plans for GLP-1 generics and capital allocation are outlined, emphasizing the balance between generics and innovative business. Finally, the M&A strategy is discussed, with a focus on in-licensing and leveraging Teva's strong pipeline.

What are Teva's plans regarding the launch of generic GLP-1 drugs?

How does Teva prioritize capital allocation between generics and innovative products?

What is Teva's strategy regarding mergers and acquisitions (M&A) in the current market?